Immunocore (IMCR) announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback